Retour

Bumrungrad Hospital Public Company Limited

Qualité des données : 100%

Suracheté

BUHPF

OTC Healthcare Medical - Care Facilities

5,65 €

0,00 € (0,00%)

Cap. Boursière : 4,49B

Également cotée sous BUGDF OTC

Fourchette du Jour

5,65 € 5,65 €

Fourchette 52 Semaines

4,75 € 5,65 €

Volume

300

Moyenne 50J / 200J

5,36 € / 4,98 €

Clôture Précédente

5,65 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique	Action	Médiane du Secteur
P/E	0,6	0,3
P/B	0,2	2,9
ROE %	25,9	3,7
Net Margin %	29,9	3,8
Rev Growth 5Y %	19,2	10,0
D/E	0,0	0,2

Objectif de Cours des Analystes

Aucune couverture d'analyste disponible

Estimations de Bénéfices

Période	BPA Est.	CA Est.	Analystes
FY2027	0,00 € 0,00 € – 0,00 €	28 B	0
FY2026	0,00 € 0,00 € – 0,00 €	26 B	0

Points Clés

Revenue grew 19,15% annually over 5 years — strong growth

ROE of 25,88% indicates high profitability

Net margin of 29,89% shows strong profitability

Debt/Equity of 0,02 — conservative balance sheet

Generating 6,59B in free cash flow

P/E of 0,60 — trading at a low valuation

Croissance

Revenue Growth (5Y)

19,15%

Revenue (1Y)-2,35%

Earnings (1Y)-3,46%

FCF Growth (3Y)10,30%

Qualité

Return on Equity

25,88%

ROIC21,22%

Net Margin29,89%

Op. Margin34,94%

Sécurité

Debt / Equity

0,02

Current Ratio4,60

Interest Coverage1324,95

Valorisation

P/E Ratio

0,60

P/B Ratio0,15

EV/EBITDA-0,30

Dividend Yield0,03%

All Fundamental Metrics

Growth
Revenue Growth (1Y)	-2,35%	Revenue Growth (3Y)	-0,52%
Earnings Growth (1Y)	-3,46%	Earnings Growth (3Y)	3,50%
Revenue Growth (5Y)	19,15%	Earnings Growth (5Y)	57,63%
Profitability
Revenue (TTM)	25,11B	Net Income (TTM)	7,51B
ROE	25,88%	ROA	20,60%
Gross Margin	50,52%	Operating Margin	34,94%
Net Margin	29,89%	Free Cash Flow (TTM)	6,59B
ROIC	21,22%	FCF Growth (3Y)	10,30%
Safety
Debt / Equity	0,02	Current Ratio	4,60
Interest Coverage	1324,95	Dividend Yield	0,03%
Valuation
P/E Ratio	0,60	P/B Ratio	0,15
P/S Ratio	0,18	PEG Ratio	-5,76
EV/EBITDA	-0,30	Dividend Yield	0,03%
Market Cap	4,49B	Enterprise Value	-2,61B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	25,11B	25,72B	25,38B	20,72B	12,46B
Net Income	7,51B	7,77B	7,01B	4,94B	1,22B
EPS (Diluted)	8,51	8,96	8,08	5,69	1,40
Gross Profit	12,69B	13,21B	12,48B	9,62B	4,73B
Operating Income	8,77B	9,17B	8,50B	6,01B	1,52B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Total Assets	36,43B	32,65B	29,21B	24,26B	20,86B
Total Liabilities	5,60B	4,85B	5,11B	4,25B	3,24B
Shareholders' Equity	30,52B	27,49B	23,80B	19,71B	17,29B
Total Debt	487,29M	139,44M	91,14M	63,28M	94,37M
Cash & Equivalents	7,59B	3,26B	3,77B	2,09B	1,80B
Current Assets	18,77B	16,73B	15,68B	11,42B	8,06B
Current Liabilities	4,08B	3,83B	4,18B	3,41B	2,28B

Scores de Stratégies

This stock passed the criteria for 4 strategies

Score = fit strength (0–100)

Rank = position among all matches

Custom Deep Value Investing (Seth Klarman)

#360 of 825

Custom Contrarian Investing (David Dreman)

#438 of 670

Value Defensive Investing (Benjamin Graham)

#514 of 709

Value Value Investing (Warren Buffett)

#120 of 203

Activité Récente

Entré Deep Value Investing (Seth Klarman)

Mar 24, 2026

Entré Contrarian Investing (David Dreman)

Mar 24, 2026

Entré Defensive Investing (Benjamin Graham)

Mar 24, 2026

Entré Value Investing (Warren Buffett)

Mar 24, 2026